Scholars Central

Conference abstractPublished 17 Oct 2016

Identification of tumor cellular origins by anchored multiplex PCR and next-generation sequencing

Authors: Craig Pierson, Laura Griffin, Josh Haimes, Laura Johnson, Russell Ryan, Aaron Berlin, Namitha Manoj, Katelyn Trifilo, Helen Wang, Skyler Mishkin, Abel Licon, Thomas Harrison, Brian Kudlow

ArcherDX Inc., USA Massachusetts General Hospital, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Tumors within the same anatomic locations often show significant heterogeneity, exhibiting diverse mutation and gene expression profiles. Distinct cellular origins or microenvironments of tumor-initiating cells have both been shown to uniquely influence the development of specific driver mutations. For example, lung cancer subtypes that arise from different anatomic locations exhibit distinct mutation profiles. Furthermore, subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) exhibit unique clinical behaviors and can be distinguished based on their cell-of-origin (COO), which can be identified based on the cellsâÂ?Â? unique gene expression patterns. Therefore, identification of a tumorâÂ?Â?s COO through gene expression profiling aids in the prediction of tumor behavior. Despite advances in next-generation sequencing (NGS) to detect mutations, these assays often cannot measure gene expression, leaving the COO elusive. ArcherÃ?® FusionPlexÃ?® assays are based on Anchored Multiplex PCR (AMPâÂ?¢), a target enrichment strategy for NGS that uses molecular barcodes that enable the counting of unique molecules to assess differences of expression levels across target genes and between samples. This allows for simultaneous mutation detection and gene expression profiling to identify COOs. We analyzed expression patterns to predict the cellular origins of several 100 lung tumor FFPE samples by performing a principle components analysis on data generated by FusionPlex Comprehensive Thyroid Lung (CTL) NGS assays. Similarly, we identified DLBCL subtypes in a small cohort of samples using the FusionPlex Pan-Heme assay. These results show that AMP-based NGS, which is used to identify multiple mutation types, can also identify the cellular origins of tumors through gene expression profiling.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Craig Pierson”
  • BylineArticles whose byline prints “Laura Griffin”
  • BylineArticles whose byline prints “Josh Haimes”
  • BylineArticles whose byline prints “Laura Johnson”
  • BylineArticles whose byline prints “Russell Ryan”
  • BylineArticles whose byline prints “Aaron Berlin”
  • BylineArticles whose byline prints “Namitha Manoj”
  • BylineArticles whose byline prints “Katelyn Trifilo”